Oral peptide bioavailability: which peptides absorb

Key takeaways

• Oral bioavailability for most peptides is under 1 to 2 percent, and often below 1 percent. Two barriers do it: the gut digests the peptide, and the intestinal lining blocks what survives .
• Oral semaglutide (Rybelsus) absorbs at roughly 1 percent of the dose, and only because it is co-formulated with the absorption enhancer SNAC, which shields it in the stomach and pushes it across the gastric wall .
• Oral octreotide (Mycapssa) lands near 0.7 percent using a different enhancer, and oral desmopressin tablets are about 0.16 percent of an intravenous dose. Both still work because the molecules are potent .
• The real outlier is cyclosporine, a cyclic, lipophilic peptide that reaches roughly 30 percent orally. Its ring structure, not a delivery trick, is why .
• Some oral peptides are not meant to absorb at all. Linaclotide (Linzess) is essentially undetectable in blood because it acts locally in the gut lumen .

The oral peptides that work, and how little of each absorbs

So when someone asks for the best oral peptide bioavailability, the honest answer is two answers. On raw percentage, cyclosporine wins, but it is a cyclic peptide and a special case. For the normal linear peptides people actually mean (the GLP-1 class and friends), roughly 1 percent with an enhancer is as good as it gets today.

Why most peptides cannot be pills

A peptide swallowed as a pill walks into a shredder. The stomach is acidic and full of pepsin. The small intestine adds pancreatic proteases (trypsin, chymotrypsin, and others) whose entire job is to chop proteins into fragments. A peptide is a protein chain, so it is the substrate those enzymes evolved to destroy .

Say some survives. It still has to cross the intestinal epithelium, and peptides are bad at it. They are large, water-loving, and often charged, which is the opposite of what slips through a cell membrane. The tight junctions between gut cells let small neutral molecules pass and hold back big hydrophilic ones. Add a plasma half-life measured in minutes once a peptide does reach the blood, and the math gets unforgiving fast .

The four ways a peptide gets into a pill anyway

Every oral peptide on the market beat the two barriers above in one of four ways.

• Add an absorption enhancer. Rybelsus carries SNAC, which locally raises the pH around the tablet to blunt enzymatic attack and helps semaglutide cross the stomach wall by the transcellular route. Mycapssa uses a transient permeation enhancer that briefly loosens intestinal tight junctions. Both buy a small, usable fraction, not a large one .
• Be potent enough that a sliver works. Desmopressin tablets deliver about 0.16 percent of an IV dose, but the effective dose is tiny to begin with, so 0.16 percent is still a therapeutic amount .
• Be a cyclic, lipophilic exception. Cyclosporine is a ring-shaped, N-methylated peptide that behaves more like a fat-soluble small molecule than a typical peptide, which is why it reaches roughly 30 percent orally with a microemulsion formulation. Most peptides are not built like this .
• Do not absorb at all. Linaclotide is a gut-acting peptide. It binds receptors on the luminal surface of the intestine and is essentially undetectable in the bloodstream. Zero systemic bioavailability is the design, not a failure .

What 1 percent actually buys you

One percent sounds like a rounding error, and for most drugs it would be. It works for oral semaglutide because semaglutide is a potent, long-acting agonist, so a small absorbed fraction still reaches concentrations that engage the GLP-1 receptor .

The price is fragility. That 1 percent is sensitive to exactly how the tablet is taken, which is why the Rybelsus label is strict: swallow it on an empty stomach with no more than about 4 ounces of plain water, then wait at least 30 minutes before eating, drinking, or taking other pills. Food and extra fluid dilute the local SNAC effect and the absorbed fraction drops . Injectable peptides do not care what you ate.

This is also why oral insulin has failed for decades. Insulin is not unusually potent, and mealtime insulin needs a fast, reproducible peak that a 1-percent, food-sensitive absorption window cannot deliver. The molecule that makes an oral pill viable has to be both potent and forgiving, and most are neither .

The honest read

Oral peptide delivery is real, but narrow. It is a handful of drugs that each cleared a specific formulation bar, not a general property you can assume for any peptide in a capsule. For the vast majority, injection is still the route that has actual human PK behind it, and an oral version either does not exist or absorbs too little and too inconsistently to matter.

If you want the full route-by-route picture (subcutaneous, intramuscular, intranasal, and the rest), see the peptide bioavailability primer. This page is the oral-only deep cut.

For research and educational purposes only. Not medical advice.

pepSmart has not commissioned independent clinical review of this article.

More on how we write and source these pieces: Editorial process and contributor disclosure and Sourcing posture.

Spot an error? Email corrections via /about.

Sources: 6 entries, all primary canon (FDA drug labels, peer-reviewed PK studies, and an NIH reference), last reviewed 2026-06-04.

Related tools

• Tirzepatide dose calculator - Run tirzepatide-focused vial draw math.
• GLP-1 conversion calculator - Convert a GLP-1 mg dose to U-100 units and ml.
• GLP-1 ramp planner - Preview a linear educational dose-step table.
• Peptide half-life calculator - Estimate single-dose decay from cited half-life constants.
• PK simulator overview - Public overview of the Pro pharmacokinetic simulator.
• Peptide reconstitution calculator - Convert vial mass and BAC water volume into mcg/ml.